Clinical Trial Update: Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial is evaluating the combination of tislelizumab with liposomal mitoxantrone in extranodal natural killer/T-cell lymphoma; the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Natural Killer T-cell Lymphoma

Drugs mentioned

• Mitoxantrone hydrochloride liposome (Mitoxantrone hydrochloride liposome)
• Tyvyt (Sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Extranodal Natural Killer T Cell Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING